188 related articles for article (PubMed ID: 33660106)
21. Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment.
Huang S; Li L; Yan N; Zhang H; Guo Q; Guo S; Geng D; Liu X; Li X
Front Oncol; 2024; 14():1331387. PubMed ID: 38706592
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer.
Chikaishi Y; Inoue M; Kusanagi K; Honda Y; Yoshida J; Tanaka M
Aging Med (Milton); 2021 Mar; 4(1):42-46. PubMed ID: 33738379
[TBL] [Abstract][Full Text] [Related]
23. A narrative review of MET inhibitors in non-small cell lung cancer with
Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
[TBL] [Abstract][Full Text] [Related]
24. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
25. Hope and Challenges: Immunotherapy in
Yan D
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001917
[TBL] [Abstract][Full Text] [Related]
26. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
Das R; Jakubowski MA; Spildener J; Cheng YW
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230737
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a
Conci N; Marchiori V; Federico AD; Giglio A; Sperandi F; Melotti B; Gelsomino F
Per Med; 2024 Jul; ():1-5. PubMed ID: 38958204
[TBL] [Abstract][Full Text] [Related]
29. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Fan S; Yu J; Lu P; Luo X; Su W
JTO Clin Res Rep; 2022 Oct; 3(10):100407. PubMed ID: 36217329
[TBL] [Abstract][Full Text] [Related]
31. Frequency of
Champagnac A; Bringuier PP; Barritault M; Isaac S; Watkin E; Forest F; Maury JM; Girard N; Brevet M
J Thorac Dis; 2020 May; 12(5):2172-2178. PubMed ID: 32642122
[TBL] [Abstract][Full Text] [Related]
32. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
33. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Jamme P; Fernandes M; Copin MC; Descarpentries C; Escande F; Morabito A; Grégoire V; Jamme M; Baldacci S; Tulasne D; Kherrouche Z; Cortot AB
J Thorac Oncol; 2020 May; 15(5):741-751. PubMed ID: 32169477
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Bylicki O; Guisier F; Monnet I; Doubre H; Gervais R; Janicot H; Perol M; Fournel P; Lamy R; Auliac JB; Chouaid C
Medicine (Baltimore); 2020 Jan; 99(3):e18726. PubMed ID: 32011450
[TBL] [Abstract][Full Text] [Related]
35. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
36. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
38. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Ichihara E; Harada D; Inoue K; Sato K; Hosokawa S; Kishino D; Watanabe K; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Lung Cancer; 2020 Jan; 139():140-145. PubMed ID: 31786476
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
40. Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation.
Nitta N; Morimoto Y; Tani N; Shimamoto T
Cureus; 2023 Feb; 15(2):e35545. PubMed ID: 37007311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]